Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231

Christian Garbar\textsuperscript{1,4}, Corinne Mascaux\textsuperscript{1,4}, Jérôme Giustiniani\textsuperscript{3,4}, Yacine Merrouche\textsuperscript{2,4} & Armand Bensussan\textsuperscript{5,6}

Autophagy is one of the chemotherapy resistance mechanisms in breast cancer. The aim of this study was to determine the level of recruitment of the autophagy pathway in the triple-negative breast cancer (TNBC) cell line MDA-MB231 compared with that in the control luminal breast cancer cell line MCF7 before and after treatment with chemotherapy drugs. Furthermore, we investigated the relationship between autophagy and EGFR, MUC1 and IL17-receptors as activators of autophagy. Immunohistochemistry was performed in cell culture blocks using LC3\textsubscript{b}, MUC1-C, EGFR, IL17A, IL17-RA and IL17-RB antibodies. We found that the basal autophagy level in MDA-MB231 was high, whereas it was low in MCF7. However, in contrast to MDA-MB231, the autophagy level was increased in MCF7 upon treatment with chemotherapy agents. Interestingly, we observed that the expression levels of MUC1-C, EGFR, IL17-RA, and IL17-RB were not modified by the same treatments. Furthermore, the chemotherapy treatments did not increase autophagy in TNBC cells without affecting the expression levels of MUC1-C, EGFR, IL17-RA or IL17-RB.

Perou’s biological and clinical classification of breast cancers (BCs) was proposed by the St Galen International Expert Consensus and is currently widely used in the clinic. This classification system proposes the following three main molecular subtypes: luminal (LUM) BC, which expresses hormonal estrogen and progesterone receptors (ER\textsuperscript{+} and PR\textsuperscript{+}) but no human epidermal growth receptor 2 (HER2-); overexpressed HER2 BC (ER\textsuperscript{+}/PR\textsuperscript{−}/HER2\textsuperscript{+}); and triple negative (TN) BC, which lacks these receptors HER2, ER and PR\textsuperscript{1,2}.

LUM BC benefits from anti-estrogen therapy, such as tamoxifen, which is an aromatase inhibitor, and HER2 BC is treated with targeted anti-HER2 (i.e., trastuzumab) therapy. Treatments of TN BC remain more challenging and are mainly based on cytotoxic chemotherapy, such as docetaxel, cyclophosphamide, fluorouracil, and epirubicine\textsuperscript{3–5}.

Autophagy is an adaptive cellular mechanism to external stress and contributes to cell survival and homeostasis. Autophagy is a complex pathway involving multiple proteins. First, autophagosomes consisting of an isolated membrane in the cytosol are activated by class I PI3K and Atg complexes, leading to nucleation, which involves Beclin-1. Finally, LC3 proteins (microtubule-associated protein 1 light chain 3) control the elongation phase, which stabilizes the autophagosomes. LC3 proteins are stable and persistent and are widely used to monitor

\textsuperscript{1}Biopathology Department, Institut Jean Godinot–Unicancer, 1 rue du Général Koenig CS80014, 51726, Reims, France. \textsuperscript{2}Oncology Department, Institut Jean Godinot–Unicancer, 1 rue du Général Koenig CS80014, 51726, Reims, France. \textsuperscript{3}Research Department, Institut Jean Godinot–Unicancer, 1 rue du Général Koenig CS80014, 51726, Reims, France. \textsuperscript{4}DERM-I-C EA7319, Université de Reims Champagne Ardenne, 51 rue Cognacq Jay, 51095, Reims, France. \textsuperscript{5}Institut National de la Santé et de la Recherche Médicale (INSERM) U976, Hôpital Saint Louis, 75010, Paris, France. \textsuperscript{6}Université Paris Diderot, Sorbonne Paris Cité, Laboratoire Immunologie Dermatologie & Oncologie, UMR-S 976, 75475, Paris, France. Correspondence and requests for materials should be addressed to C.G. (email: christian.garbar@reims.unicancer.fr)

Received: 15 February 2017
Accepted: 27 June 2017
Published online: 03 August 2017
autophagy6. Tumor cells exhibit a basal level of autophagy activity that could be increased upon exposure to anoxia, starvation, chemical agents and radiation.

Chemotherapy resistance is due to multiple mechanisms, including autophagy. For example, in breast cancer, epirubicin reduces autophagy and protects cells from chemotherapy-induced apoptosis. Moreover, in colorectal cancer, oxaliplatin and 5-fluorouracil were found to have an improved efficiency in the presence of an anti-autophagy agent, whereas in lung cancer, anti-EGFR agents (i.e., gefitinib or erlotinib) activate autophagy and induce drug resistance7.

MUC1 is a large transmembrane O-glycosylated heterodimer protein that consists of a large, broadly glycosylated extracellular α-subunit containing 20 to 125 tandem repeats of 20 amino acids (MUC1-VNTR) and a β-subunit containing the transmembrane domain and a cytoplasmic tail (MUC1-C)8–10. The β-subunit is involved in several cellular signaling pathways, such as growth/survival pathways and the induction or inhibition of apoptosis11,12. Moreover, MUC1 expression is associated with an increased lysosomal turnover of the autophagy maker LC3 after stimulation of the AMP-activated protein kinase (AMPK), which is involved in the regulation of autophagy13. Some authors have demonstrated that the β-subunit of MUC1 and EGFR are both co-localized in the cell membrane and nucleus and are involved in the internalization of EGFR and the activation of the EGFR-PI3K-AKT-mTOR pathway14–17. Interestingly, this pathway is a key regulator of autophagy, and activated mTOR inhibits autophagy.

ERK1/2 is an autophagy activator. Additionally, our team has recently shown that IL17A is produced by BC TILs and plays a role in docetaxel chemoresistance and proliferation through the ERK1/2 pathway18. We also reported that IL17A and IL17B receptor transcripts are overexpressed in BCs and that the activation of the IL17E receptor, i.e., the heterodimer of IL17A and IL17B receptors, induces EGFR phosphorylation and migration to the nucleus. We have also suggested that the inhibition of IL17E could enhance the efficacy of anti-EGFR chemotherapy19,20.

To better understand the relationship between autophagy and the chemotherapy resistance of TN BC, we used a cell culture model consisting of a TNMDA-MB231 cell line and an MCF7 LUM control cell line with or without a treatment with sub-lethal concentrations of chemotherapy agents. We then performed immunohistochemistry to measure the expression levels of LC3b, which is an autophagy marker, and the targeted antigens MUC1, EGFR, IL17RA and IL17RB, which are known to be involved in autophagy and chemoresistance.

Results

Basal autophagy level is high in MDA-MB231 cells and is not influenced by chemotherapy drugs. The MDA-MD231 cell line consists of triple-negative breast cancer cells that do not express estrogen and progesterone receptors or HER2. These characteristics are conserved in the cells upon exposure to chemotherapy agents (data not shown). When cultured in the control medium, LC3b staining was higher in the in MDA-MD231 cells than in the MCF7 cells (Fig. 1). Compared with cells cultured in the control medium, cells cultured with epirubicin exhibited a significantly decreased basal level of autophagy. Importantly, the autophagy level in the MDA-MD231 cells cultured with cyclophosphamide, docetaxel and 5-FU was similar to that in the MDA-MD231 cells cultured in the control culture (Fig. 2).

Basal autophagy is low and increases with chemotherapy drugs in MCF7 cells. MCF7 cells are a luminal cancer cell line expressing estrogen and progesterone receptors but not HER2. These characteristics were conserved upon exposure to chemotherapy agents (data not shown). Interestingly, as shown in Fig. 3, MCF7 cells treated with the autophagy inhibitor epirubicin still had the same low basal level of autophagy as the MCF7 cells cultured in the control medium (control medium MCF7 vs control medium MDA-MB231: p = 0.006, control medium MCF7 vs epirubicin MDA-MB231: p = 0.45) and that treatments with cyclophosphamide, docetaxel and 5-fluorouracil (5-FU) significantly enhance the level of autophagy.

Expression levels of MUC1, EGFR, IL17-RA and IL17-RA are not influenced by chemotherapy. We have recently described that luminal breast cancer cells widely express MUC1 and exhibit a low level of EGFR in situ, whereas triple-negative breast cancer cells are negative for MUC1 and positive for EGFR21. Here, we confirmed these results using the luminal breast cancer cell line MCF7 and the triple-negative breast cancer cell line MDA-MB231. Interestingly, we observed no differences in the expression of MUC1 or EGFR in the MCF7 or MDA-231 cell cultures treated with the control medium alone, the autophagy inhibitor epirubicin, or chemotherapy drugs (Figs 4 and 5).

IL17A is known to inhibit autophagy22. We have previously demonstrated that IL17A transcripts are not detected in breast cancer cell lines, although these cell lines do express IL17RA and IL17RB transcripts23. In the present work, specific antibodies were used for the first time, and we confirmed our previous results: IL17A is not expressed in any culture cells (Fig. 6) comparatively to IL17-RA (Fig. 7). Moreover, we also observed a lower level of IL17RB in the MDA-MD231 cells than in the MCF7 cells (Fig. 8). Interestingly, the expression of IL17RA and IL17RB was not influenced by the chemotherapy drugs (Figs 7 and 8), and IL17A remained negative (Fig. 6).

Discussion

In the present study, we performed an analysis investigating the recruitment of the autophagy pathway in triple-negative cancer cells. The luminal cancer cells showed a low level of autophagy, which was increased by chemotherapy drugs. However, epirubicin, which is a known autophagy inhibitor, failed to induce this enhancement7. By contrast, the triple-negative cancer cells showed a high level of autophagy, which was not influenced by the chemotherapy drugs. Interestingly, epirubicin reduced the basal level of autophagy.

This high level of autophagy in TN BC has already been observed in vitro and in vivo by Lefort S. et al. in a large cohort of BC cells. These authors demonstrated that TN BC shows significantly more autophagosomes
(measured by LC3b) than LUM or HER2 BC. Furthermore, these authors demonstrated that the LC3b protein is a marker of a poor prognosis in TN BC patients using immunohistochemistry on paraffin embedded biopsy tissue\textsuperscript{23}. Using a mouse model, chloroquine, which is an autophagy inhibitor, was demonstrated to potentiate chemotherapy against human TN BC\textsuperscript{23}.

The aim of our present work was to establish a kinetic cell culture model to better understand chemoresistance. We found that TN BC (MDA-MB231) and LUM (MCF7) cells exhibit a different strategy against...
chemotherapy drugs. TN BC has an already high initial level of autophagy, whereas LUM exhibits increased autophagy in response of chemotherapy. These cell strategy differences could be explained by the dual paradoxical role of autophagy against therapeutic anticancer drugs, which either induce cell death or promote cell survival7. It is easy to understand that treatment against autophagy will yield different results in the same tumors and across tumor subtypes, leading to a true targeted therapy.

The ERK1/2 signaling pathway is a key component of autophagy. Sivaprasad U et al. demonstrated that TNF activates autophagy in MCF7 BC and that the pharmacological inhibition of ERK1/2 was associated with a decrease in TNF-induced autophagy (LC3b)24. In similar cell models using MCF7 and MDA-MB231 cell lines, Shen P. et al. demonstrated that gemcitabin induces autophagy with a cytotoxic effect in MCF7 cells and a cytoprotective effect in MDA-MB231 cells. The cytotoxic effect in MCF7 cells is attributed to the cascade of estrogen receptor-ERK-p62, which could be inactivated by specific siRNA. Furthermore, these authors showed that gemcitabin is able to induce mTOR-independent autophagy in MDA-MB231 cells also via the ERK1/2 pathway7, 25, 26.

Interestingly, our team demonstrated that IL17A promotes chemoresistance to docetaxel and proliferation through ERK1/2 signaling in the MCF7, T47D, BT20, MDA468 and MDA157 cell lines 18, 19. We also showed that IL17A is produced by tumor-infiltrating lymphocytes isolated in biopsies from six patients with TN BC. The mechanism of this chemoresistance is not currently understood, but inhibition of the autophagy pathway in TN BC is likely the best candidate. Indeed, Zhou Y. et al., using a hepatocellular carcinoma cell culture model, demonstrated that IL17A promotes the migration of tumor cells and prevents autophagic cell death22. Our previous studies also demonstrated that MCF7 and MDA-MD231 cells do not express IL17A mRNA, but do express the transcripts of its receptor IL17RA. Furthermore, we found that MCF7 cells expressed IL17RB mRNAs, whereas MDA-MB231 cells only expressed a low level of IL17RB mRNA. The present study confirmed these observations using immunohistochemistry. We recently described the possible synergy between EGF and IL17RE to confer resistance against anti-EGFR therapy20. Here, we illustrated that protein expression of IL17RA, IL17RB, EGFR and MUC1 is not altered by chemotherapy and, consequently, that these proteins could be accessible for specific targeted therapy. It should be noted that in this study, we also confirmed in vitro our previous in vivo observations indicating that TN BC cells present a low level of MUC1 and a high level of EGFR and that LUM BC cells show the opposite pattern21. Moreover, MUC1 expression is correlated with an increased lysosomal turnover of the autophagic maker LC3, suggesting that MUC1 plays a role in the regulation of autophagy27.

Recently, Hiraki M et al. demonstrated, using the TN BC cell line MDA-MB468, that MUC1-C activated the MEK-ERK and PI3K-AKT pathways, and both activated autophagy. These authors concluded that targeting MUC1-C is a potential strategy for reversing resistance in TN BC24. We do not completely agree with this hypothesis because in our experience, both in vivo and in vitro, TNBC shows no or low levels of MUC1-C25. Another study using MCF7 and ZR-75-1 cell lines treated with an inhibitor of MUC1-C (GO-203) demonstrated an increase in the apoptotic response to Taxol and doxorubicin25. It is known that the MUC1-C cytoplasmic domain interacts with numerous regulator proteins, such as NF-B, p53 and PI3k22. As discussed above, the PI3K-AKT-mTOR pathway is involved in autophagy. Recently, we have demonstrated that PI3K-p110β and MUC1-C are more highly expressed in LUM than in TN BC25. This finding suggests that BC cell autophagy activation strategies could involve the MUC1-PI3K-AKT pathway in LUM BC and the IL17-ERK pathway in TN BC.

In conclusion, this study illustrated the different strategies of inducing autophagy in MDA-MB231 and MCF7 cells in response to chemotherapy. Further studies should be performed to confirm our hypothesis and identify the ideal strategy for anti-autophagy adjuvant therapy to avoid chemotherapy resistance in each BC subtype.
Materials and Methods

Cell cultures and reagents. The MCF7 and MDA-MB231 cell lines were obtained from England Type Culture Collection (Salisbury). The cells were cultured in DMEM medium (VWR International SAS, Fontenay-sous-bois, France) supplemented with 10% Fetal Calf Serum (FCS), 2% glutamine and 1% penicillin/streptomycin.

Figure 4. MUC1-C expression in MCF7 and MDA-MB231 cells. MUC1-C expression in MCF7 (a–e) and MDA-MB231 cells (f–j) without drugs or (a,f) with cyclophosphamide (b,g), doxorubicin (c,h), epirubicin (d,i) or 5-fluorouracil (e,j). Note the higher expression of MUC1-C in the MCF7 cells than that in the MDA-MB231 cells, but no changes were observed with the chemotherapy drug treatments. The MUC1-C antibody was diluted 1/400 (40x magnification).
antibiotics (Dutscher SAS, Brumath, France). All cells were kept at 37 °C in a 5% CO2 atmosphere incubator. Then, each cell line was incubated with a sub-lethal chemotherapy drug concentration calculated according to the mean of the metabolic activity as measured by Rotitest Vital® (Carl Roth EURL, Lauterbourg, France) and a spectrophotometer (iMark TM, Bio-Rad, France) as follows: the final concentrations consisted of only

Figure 5. EGFR expression in MCF7 and MDA-MB231 cells. EGFR expression in MCF7 (a–e) and MDA-MB231 cells (f–j) without drugs or (a.f) with cyclophosphamide (b.g), doxorubicin (c.h), epirubicin (d.i) or 5-fluorouracil (e.j). Note the higher expression of EGFR in the MDA-MB231 cells than that in the MCF7 cells, but no changes were observed with the chemotherapy drug treatment. The EGFR antibody was diluted 1/200 (40X magnification).
DMEM in the control culture, 5 µg/ml in the epirubicin culture, 10 µg/ml in the docetaxel culture, 10 µg/ml in the 5-fluorouracil culture and 10 µg/ml in the cyclophosphamide culture. The chemotherapy drugs were added, and cell blocks were performed the following day. Each cell culture was replicated 3 times for the cell blocks and immunohistochemistry.

**Figure 6.** IL17A expression in MCF7 and MDA-MB231 cells. IL17A expression in MCF7 (a–e) and MDA-MB231 cells (f–j) without drugs or (a,f) with cyclophosphamide (b,g), doxorubicin (c,h), epirubicin (d,i) or 5-fluorouracil (e,j). No significantly positive signals were observed in any of the cultures. The IL17a antibody was diluted 1/800 (40x magnification).
Cell block. After washing with PBS and treating with trypsin, the cell cultures were centrifuged at 1300 RPM for 8 min. Then, the cell pellets were fixed in 5 ml of 4% buffered formaldehyde solution for 8 to 48 hours. The cells were centrifuged at 1000 RPM for 5 min. The pellets were prepared using a Cytoblock® kit (Thermo Fisher Scientific, Brebieres, France) and then embedded in paraffin. The paraffin-embedded cell blocks were cut into 4µm thick sections for the immunohistochemistry.

Figure 7. IL17RA expression in MCF7 and MDA-MB231 cells. IL17RA expression in MCF7 (a–e) and MDA-MB231 cells (f–j) without drugs or (a,f) with cyclophosphamide (b,g), doxorubicin (c,h), epirubicin (d,i) or 5-fluorouracil (e,j). All cell cultures show a positive cytoplasmic signal, but no changes were observed with the chemotherapy drug treatments. The IL17RA antibody was diluted 1/800 (40x magnification).
Immunohistochemical Methods. Immunohistological staining was performed using a Dako Autostainer Link 48® immunostaining system (Dako Glostrup, Denmark). After dewaxing, the antigenic retrieval was performed using citrate buffered (pH 6) or EDTA buffered (pH 9) antigenic retrieval solution at 99 °C in a warm bath (EnVision Flex Target Retrieval solutions with a high and low pH, Dako). Endogenous peroxidase was inhibited.
Table 1. Primary antibodies, dilution, antigenic retrieval, incubation times and abbreviations used in this study.

| Antibodies                        | Clone       | Abbreviation | Manufacture | Dilution | Retrieval | Incubation (minutes) |
|-----------------------------------|-------------|--------------|-------------|----------|-----------|----------------------|
| EGFR wild-type                    | DAK-H1-WT   | EGFR         | Dako        | 1: 200   | pH9       | 30                   |
| MUC1-ter C                        | ARF41446    | MUC1-CT      | Aviva Syst. Biology | 1: 400   | pH9       | 60                   |
| α- Estrogen receptor              | SP1         | ER           | Dako        |          | RTU       | pH9                  | 20                   |
| Pregesteron receptor              | PgR636      | PR           | Dako        | 1: 800   | pH9       | 20                   |
| HER2                              | c-Erb2      | HER2         | Dako        |          | RTU       | pH9                  | 30                   |
| LC3b                              | poly        | LC3b         | Abcam       | 1: 400   | pH6       | 60                   |
| IL17a                             | poly        | IL17A        | Abcam       | 1: 800   | pH6       | 60                   |
| IL17RA                            | 49M4D2      | IL17RA       | Cliniscience | 1: 800   | pH6       | 60                   |
| IL17RB                            | 97C691      | IL17RB       | Cliniscience | 1: 40    | pH6       | 60                   |

with a hydrogen peroxide phosphate buffered solution (EnVision Flex Peroxidase Blocking Reagent, Dako). After incubating with the primary antibodies, the immunological reaction was revealed by a polymer dextran coupled with the secondary antibody and peroxidase for 15 min (EnVision Flex HRP, Dako) and diaminobenzidine for 10 minutes (EnVision DAB+ chromogen, Dako). Counterstaining was performed with hematoxylin for 10 min (EnVision Flex hematoxylin, Dako). Negative controls were obtained using mouse or rabbit IgG1 (Universal Negative Control Mouse or Universal Negative Control Rabbit, Dako) instead of the primary antibodies for each culture. No specific signal was observed. The primary antibodies, dilutions and antigenic retrieval are described in Table 1 (Table 1).

Immunostaining quantification. The staining results were evaluated by C.G. and C.M. Only LCB3 was quantified and is expressed as the mean and SD of the cytoplasmic dots signals (autophagosomes) in 100 cells at 100x magnification (Fig. 1). Other immunohistochemical staining was evaluated as positive or negative.

Statistics. The results are expressed as the means and standard error. Mann-Whitney tests were performed. A p-value <0.05 was considered significant. The WinSTAT® version 2012 (Fitch Software, Bad Krozingen, Germany) and Excel 2013 (Microsoft Corp., Redmond, Washington U.S.A.) programs were used for the statistical analysis.

References

1. Perou, C. M. Molecular stratification of triple-negative breast cancers. Oncologist. 16, 61–70 (2011).
2. Goldhirsch, A. et al. Panel embers. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 24, 2206–23 (2013).
3. Baselga, J. et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol. 31, 2386–92 (2013).
4. Lehmann, B. D. & Pietenpol, J. A. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 232, 142–50 (2014).
5. Joensuu, H. et al. Adjutant Cetuximab in combination with Docetaxel, Epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical finXX trial. JAMA Oncol. (2017).
6. He, C. & Klionsky, D. J. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. 43, 67–93 (2009).
7. Sui, X. et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis. 10(4), e838 (2013).
8. Baruch, A. et al. Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function. Int J Cancer. 71, 741–9 (1997).
9. Joshi, M. D. et al. MUC1 oncoprotein is a druggable target in human prostate cancer cells. Mol Cancer Ther. 8, 3056–65 (2009).
10. Rubinstein, D. B. et al. MUC1/X protein immunization enhances cDNA immunization in generating anti-MUC1 alpha/beta junction antibodies that target malignant cells. Cancer Res. 66, 11247–53 (2006).
11. Bafna, S., Kaur, S. & Batra, S. K. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene. 29, 2893–904 (2010).
12. Raina, D., Kharbanda, S. & Kufe, D. The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xl pathways in rat 3Y1 fibroblasts. J Biol Chem. 279, 20607–12 (2004).
13. Yin, L., Kharbanda, S. & Kufe, D. MUC1 oncoprotein promotes autophagy in a survival response to glucose deprivation. Int J Oncol. 34, 1691–9 (2009).
14. Bitler, B. G., Goverdhan, A. & Schroeder, J. A. MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. J Cell Sci. 123, 1716–23 (2010).
15. Kufe, D. W. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. 32, 1073–81 (2013).
16. Dharmaraj, N., Engel, B. J. & Carson, D. D. Activated EGFR stimulates MUC1 expression in human uterine and pancreatic cancer cell lines. J Cell Biochem. 114, 2314–22 (2013).
17. Lau, S. K. et al. EGFR-mediated carcinoma cell metastasis mediated by integrin αv/β5 depends on activation of c-Src and cleavage of MUC1. PloS One. 7, e36753 (2012).
18. Cochaud, S. et al. IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. Sci Rep. 3, 3456 (2013).
19. Mombelli, S. et al. IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells. Sci Rep. 5, 11874 (2015).
20. Merrouche, Y. et al. IL-17E synergizes with EGFR and confers in vitro resistance to EGFR-targeted therapies in TNBC cells. Oncotarget. 7, 53350–61 (2016).
21. Garbar, C. et al. Autophagy is decreased in triple-negative breast carcinoma involving likely the MUC1-EGFR-NEU1 signalling pathway. Int J Clin Exp Pathol. 8, 4344–55 (2015).
22. Zhou, Y., Wu, P. W., Yuan, X. W., Li, J. & Shi, X. L. Interleukin-17A inhibits cell autophagy under starvation and promotes cell migration via TAB2/TAB3-p38 mitogen-activated protein kinase pathways in hepatocellular carcinoma. *Eur Rev Med Pharmacol Sci.* **20**, 250–63 (2016).

23. Lefort, S. *et al.* Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers. *Autophagy* **10**, 2122–42 (2014).

24. Sivaprasad, U. & Basu, A. Inhibition of ERK attenuates autophagy and potentiates tumour necrosis factor-alpha-induced cell death in MCF-7 cells. *J Cell Mol Med.* **12**, 1265–71 (2008).

25. Shen P. *et al.* Inhibition of EROS/ERK/P62 cascades induces “autophagic switch” in the estrogen receptor-positive breast cancer cells exposed to gemcitabine. *Oncotarget* **7**, 01–48516 (2016).

26. Chen, M. *et al.* The cytoprotective role of gemcitabine-induced autophagy associated with apoptosis inhibition in triple-negative MDA-MB-231 breast cancer cells. *Int J Mol Med.* **34**, 6–82 (2014).

27. Yin, L., Kharbanda, S. & Kufe, D. MUC1 oncoprotein promotes autophagy in a survival response to glucose deprivation. *Int J Oncol.* **34**, 1691–9 (2009).

28. Hiraki, M. *et al.* MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors. *Sci Rep.* **6**, 26643 (2016).

29. Uchida, Y., Raina, D., Kharbanda, S. & Kufe, D. Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells. *Cancer Biol Ther.* **14**, 127–34 (2013).

30. Raina, D., Kharbanda, S. & Kufe, D. The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. *J Biol Chem.* **279**, 20607–12 (2004).

**Author Contributions**

C.G. and A.B. designed and supervised the study and wrote the manuscript text and figures. C.M. and C.G. performed the experiments. All authors reviewed the manuscript (C.G., A.B., Y.M., J.G.).

**Additional Information**

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017